BrightSpring Health Q2 revenue beats estimates as revenue jumps
BTSG•Updated 2026 outlook
- BrightSpring raised 2026 revenue guidance to $15.1 billion-$15.425 billion, up 17%-19.5%.
- Company lifted its 2026 adjusted EBITDA forecast to $820 million-$845 million, up 32.8%-36.8%.
- The Amedisys and LHC branches acquisition is expected to add about $35 million to 2026 adjusted EBITDA.
Drivers of the quarter
- Pharmacy Solutions - The company said revenue per prescription rose 22% yr/yr, driving segment revenue growth.
- Gross profit per script - BrightSpring reported gross profit per script up 28% yr/yr in the Pharmacy Solutions segment.
- Provider Services - The segment saw a 54% yr/yr increase in average daily home health care census.
Key figures and analyst view
| Metric | Beat/Miss | Actual |
|---|
